The O-Cyte 1 system addresses the persistent challenge of managing rising clinical workloads while maintaining precise morphological analysis. Rather than displacing existing expertise, the platform adds an image-based layer to standard blood cell counts, allowing technicians to view cellular evidence alongside numerical results. This approach ensures that diagnostic clarity remains consistent even as testing volumes climb.
Scalability serves as a core feature of the new hardware. The analyzer processes 60 tests per hour as a standalone unit, with a cascaded configuration capable of handling up to 360 tests per hour. Beyond sheer throughput, the design focuses on reducing maintenance requirements through consumable-contained fluidics and a modular architecture. These features allow for deployment across diverse settings, ranging from localized health screening centers to expansive regional diagnostic networks.
Alongside this launch, Ozelle showcased a broader portfolio of integrated diagnostic tools, including multi-test systems that merge hematology with immunoassay and biochemistry capabilities. This transition signals a strategic shift for the company, moving away from isolated instruments toward interconnected systems tailored for the realities of modern clinical diagnostics. Following the Anaheim debut, the firm plans to begin global implementation and collaborative trials with healthcare organizations to refine the application of AI-driven morphology in professional settings.

Comments (0)
No comments yet. Be the first!